Bavarian Nordic A/S

<!-- Name:DistributionId Value:1000796443 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000795785 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000784648 --> <!-- Name:NewsArchiveOrgTags Value:2887#Financial release;2886#Regulatory release;MyWeb#My Website -->…

<!-- Name:DistributionId Value:1000784295 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000783739 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000783676 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000782742 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000782730 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags…

All-time high revenues and EBITDA profitability for 2022 COPENHAGEN, Denmark, January 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported preliminary, unaudited financial results for 2022, exceeding the financial guidance for the…

Total considerations of up to USD 83 million with the majority secured for Phase 2 development of the multivalent MVA-BN® WEV vaccine candidate, in addition to options for Phase 3 preparatory work COPENHAGEN, Denmark, December 23,…